Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 269055-15-4
Drug Levels and Effects
Summary of Use during Lactation
Etravirine is excreted in breastmilk in concentrations exceeding the maternal plasma and appears to increase in concentration over time. Until more information becomes available, an alternate agent may be preferred. In the US and other countries where access to clean water and affordable replacement feeding are available, it is recommended that mothers living with HIV not breastfeed their infants to avoid postnatal transmission of HIV-1 infection.
Drug Levels
Maternal Levels. Nine HIV-positive women had etravirine added to their existing antiretroviral regimens between postpartum days 1 and 14 postpartum. The dosage was not stated, but was presumably 200 mg twice daily. Breastmilk and maternal serum samples were obtained at 0, 2, 5, 8 and 24 hours after the dose of etravirine on days 5 and 14 postpartum. The median breastmilk concentration of etravirine on day 5 was 241 mcg/L (range 161 to 891 mcg/L) and on day 14 was 798 mcg/L (range 161 to 2714 mcg/L). The median milk to plasma ratio was 1.09 on day 5 and 3.27 on day 14.[1]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Spencer LY, Liu S, Wang CH, et al. Intensive etravirine PK and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART. Topics Antiviral Med. 2014;22:466. https://www
.iasusa.org/tam/april-2014 [Abstract].
Substance Identification
Substance Name
Etravirine
CAS Registry Number
269055-15-4
Drug Class
Breast Feeding
Milk, Human
Anti-Infective Agents
Antiviral Agents
Anti-HIV Agents
Anti-Retroviral Agents
Reverse Transcriptase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Rilpivirine.[Drugs and Lactation Database (...]Review Rilpivirine.. Drugs and Lactation Database (LactMed®). 2006
- Review Doravirine.[Drugs and Lactation Database (...]Review Doravirine.. Drugs and Lactation Database (LactMed®). 2006
- Review Maraviroc.[Drugs and Lactation Database (...]Review Maraviroc.. Drugs and Lactation Database (LactMed®). 2006
- Review Bictegravir.[Drugs and Lactation Database (...]Review Bictegravir.. Drugs and Lactation Database (LactMed®). 2006
- Review Ritonavir.[Drugs and Lactation Database (...]Review Ritonavir.. Drugs and Lactation Database (LactMed®). 2006
- Etravirine - Drugs and Lactation Database (LactMed®)Etravirine - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...